Computational Drug-DDS Engineering · CEREBRO-X | Nusinersen
| Parameter | Value | Method |
|---|---|---|
| ΔG single ligand | -5.00 kcal/mol | LIE (Aqvist 1994) |
| ΔG avidity | -2.59 kcal/mol | Bell cooperative binding |
| Receptors engaged | 50 | Geometric model |
| Kd class | Weak (>100nM) | Equilibrium binding |
Ligand-receptor docking uses Linear Interaction Energy (LIE) approximation. Avidity computed via Bell 1978 multi-valent model. Higher avidity = longer residence = more transcytosis events.
Docking affinity → release kinetics correlation
Endosomal escape efficiency vs release rate
Purple bands = sleep (00:00–08:00), 3.5× faster clearance (Xie 2013, Science). ECM binding index 0.48: particles mobile — faster clearance.
DLVO theory: V_total = V_vdW (attraction) + V_EDL (electrostatic repulsion). Threshold 25kT prevents aggregation in blood. Debye length = 0.78 nm (physiological ionic strength).
SHAP (SHapley Additive exPlanations) shows contribution of each feature to the final score. Green = positive contribution. Red = negative. Based on gradient boosted ensemble model.
→ No mitigation needed
| Capability Dimension | Score | Modules Active |
|---|---|---|
| BBB Engineering | 100% | ✅ |
| PK Prediction | 95% | ✅ |
| Safety Screening | 90% | ✅ |
| Manufacturing | 85% | ✅ |
| Regulatory (FDA) | 90% | ✅ |
| Clinical Translation | 80% | ✅ |
| IP & Economics | 85% | ✅ |
| Stability | 90% | ✅ |
| Severity | Problem Identified | Evidence | DDS Solution | Expected Outcome |
|---|---|---|---|---|
| CRITICAL | Large molecular weight -- passive BBB diffusion impossible | MW = 1.6 kDa (Lipinski Rule 5 limit: 500 Da for passive) | lnp encapsulation (75% EE) | Active transcytosis delivers 10.0% paylo |
| Step | Setting |
|---|---|
| Freezing | -50°C @ 1°C/min |
| Primary drying | -32°C, 0.148 mbar |
| Secondary drying | +25°C, 0.05 mbar |
| Tg' safety margin | -2.0°C above Tg' |
| Cake collapse risk | OK: Tg within safe margin |
Excursion Temperature: -20°C for 4h
Lipid Tm: 42°C
ΔT above Tm: -62.0°C
Leakage rate: 0.000100 /h
Analytical check: Re-test DLS particle size + HPLC drug content before release
FUS + microbubbles open BBB via stable cavitation (MI 0.3-0.5). Inertial cavitation (MI>0.8) = irreversible damage. Carrier injected 5 min before FUS for optimal uptake.
Structural integrity: OK
For Nusinersen, the Top-1 DDS achieved a composite score of 76.3/100 (GOOD). Below are the CNS group rollups followed by the FULL 62-principle scoreboard covering all three pipeline classes: A (Surrogate) B (Deep) C (Translational)
| P# | Class | Title | Score | Conf. | Method | Reference |
|---|---|---|---|---|---|---|
| P01 | A | Adversarial Stress-Testing Engine | 53.4 | MODERATE | Mean of 6 stress scenarios (pH4.5, pH2, pH8.5, 42°C, complement, oxidation); each sce | Anchordoquy TJ et al (2017) ACS Nano 11:12 |
| P02 | A | Cross-Species PK Scaling (Allometric) | 75.0 | MODERATE | BW^0.75 scaling + class-specific adjustment | Mahmood I (2007) Eur J Drug Metab Pharmacokinet 32 |
| P03 | A | Competitive DDS Landscape Radar | 100.0 | LOW | Novelty = 100 - frequency_of_combo_in_CNS_trials, modified by whether the drug's LogP | ClinicalTrials.gov landscape |
| P04 | A | Quantum Coherence Transport Model | 27.1 | MODERATE | WKB tunneling: P ∝ exp(-2·barrier) | Cao J et al (2020) Sci Adv 6:eaaz4888 |
| P05 | A | In-Silico Patient Subgroup Stratifier | 100.0 | MODERATE | % subgroups responding (lower CYP risk = more universal) | Whirl-Carrillo M et al (2012) Clin Pharmacol Ther |
| P06 | A | Lysosomal Trafficking Predictor | 58.4 | MODERATE | Carrier endosomal_escape ⊕ drug-passive permeation at pH 5.5; drug-passive = LogP-dri | Smith SA et al (2019) Trends Biotechnol 37:1077 |
| P07 | A | Real-Time Literature Mining (PubMed) | 80.0 | LOW | log-count proxy of literature support | NCBI E-utilities — heuristic (no live fetch in sur |
| P08 | A | Degradation Kinetics Under Oxidative Stress | 43.0 | MODERATE | Arrhenius k=A·exp(-Ea/RT) for carrier; minus penalties for drug-side oxidation-prone | Halliwell B & Gutteridge JMC (2015) Free Radicals |
| P09 | A | Digital Pharmacovigilance Engine | 100.0 | MODERATE | 100 - sum(metabolite organ accumulation risks) | Djoumbou-Feunang Y et al (2019) J Cheminform 11:2 |
| P10 | A | LNP Ionization State Predictor | 60.0 | LOW | Non-LNP carrier — falls back to drug-side ionization stability at storage pH 7.4 (low | Hafez IM et al (2001) Adv Drug Deliv Rev 47:139 |
| P11 | A | Formulation Instability Fingerprint | 100.0 | MODERATE | 100 - sum(weak-bond penalties from SMILES) | Luo YR (2007) Comprehensive Handbook of BDE |
| P12 | A | CNS Disease-Stage-Aware Dosing | 83.0 | MODERATE | Score = 100·BBB_integrity_factor × (0.4 + 0.6·CNS-MPO/6) + targeting_boost (larger bo | Sweeney MD et al (2018) Nat Rev Neurol 14:133; Wag |
| P13 | A | PBPK Digital Twin | 0.7 | MODERATE | AUC_brain/AUC_plasma proxy; 3-compartment surrogate | Hammarlund-Udenaes M et al (2008) Pharm Res 25:173 |
| P14 | A | In-silico Dissolution & Release Profile | 100.0 | MODERATE | t50 from carrier kinetics × drug-membrane partition factor (10^logK_mem); HBD-anchori | Costa P & Lobo JM (2001) Eur J Pharm Sci 13:123; H |
| P15 | A | Shelf-life & Degradation Predictor | 46.2 | MODERATE | Arrhenius baseline × (0.7 + 0.3·EE) × drug_hydrolysis_factor (0.08 penalty per hydrol | Kennon L (1964) J Pharm Sci 53:815; ICH Q1A(R2) |
| P16 | A | Scale-up & Manufacturability | 48.0 | MODERATE | Scale-readiness × shear-robustness, minus drug-processability penalties (MW, HBD-crys | am Ende DJ (2011) Chemical Engineering in Pharma I |
| P17 | A | Nanotoxicity & Immunogenicity Screening | 83.8 | MODERATE | Mean of (hemolysis penalized by drug net+ charge, complement penalized for biologics, | Nel A et al (2006) Science 311:622 |
| P18 | A | Active Targeting & Receptor Binding | 85.4 | HIGH | Ligand-affinity table × density × drug-compatibility (receptor-pathway-specific drug | Pardridge WM (2020) Fluids Barriers CNS 17:62 |
| P19 | A | QbD - Quality by Design Engine | 100.0 | MODERATE | Fraction of CQAs (size, zeta, EE, PDI, drug-loading) within ICH spec — 5th CQA depend | ICH Q8(R2) Pharmaceutical Development; Bunjes H (2 |
| P20 | A | Cost-Efficiency Engine | 62.8 | LOW | Score = 100 - 3·($/mg estimate, drug+carrier+ligand+API). Drug API cost from stereoce | Cost-of-goods analysis (Pharm Eng J 2019); Walsh G |
| P21 | C | Pre-IND Regulatory Reports | 0.0 | — | skipped_deep_validation_insufficient | |
| P22 | A | Protein Corona Predictor | 79.3 | MODERATE | 100 × exp(-corona_thickness/10); thickness from carrier (|zeta|, size) + drug-side (L | Tenzer S et al (2013) Nat Nanotechnol 8:772; Schöt |
| P23 | A | Dynamic Crystal Polymorphism | 80.0 | MODERATE | 100 - polymorph risk (rot_bonds + H-bond pattern) | Bernstein J (2020) Polymorphism in Molecular Cryst |
| P24 | A | Shear-Stress & Scale-Up Collapse | 59.6 | MODERATE | log10(crit_shear/operating_shear) × 30; crit_shear softened by drug-load for lipid ca | Maa YF & Hsu CC (1996) Biotechnol Bioeng 51:458; B |
| P25 | A | Extractables & Leachables | 100.0 | MODERATE | 100 - leachables risk by drug LogP × carrier | USP <1663>/<1664> |
| P26 | A | Microbiome-Excipient Interactions | 78.0 | MODERATE | 100 - mean_microbiome_degradability(carrier) - drug-side risk (anionic-fraction, pola | Zimmermann M et al (2019) Nature 570:462 |
| P27 | A | Lyophilization Cycle Optimizer | 62.5 | MODERATE | 100 - (|Tg'| - 5) × 1.5 | Pikal MJ (2002) Pharmaceutical Lyophilization |
| P28 | A | 3D-Printed Polypill Rheology | 50.0 | MODERATE | Carrier-specific printability index | Trenfield SJ et al (2019) Adv Drug Deliv Rev 138:1 |
| P29 | A | Biomimetic & Exosome Engineering | 65.0 | MODERATE | Stealth-from-macrophage score; PEG ≥5% boost | Hu CMJ et al (2011) PNAS 108:10980 |
| P30 | A | QM/MM Stimuli-Responsive Cleavage | 45.0 | MODERATE | Score = 50 × |7.4 - pH_trigger| | Senn HM & Thiel W (2009) Angew Chem Int Ed 48:1198 |
| P31 | A | In-Silico Biodistribution | 0.4 | MODERATE | brain% = BBB · ligand · size_match · 100; 100 if ≥5% | Wilhelm S et al (2016) Nat Rev Mater 1:16014 |
| P32 | C | Automated FTO & IP Evader | 0.0 | — | skipped_deep_validation_insufficient | |
| P33 | A | BBB Quantum Breaker (Trojan-Horse Design) | 54.6 | MODERATE | (0.6·ligand + 0.4·size) × density_factor | Pardridge WM (2020) Fluids Barriers CNS 17:62 |
| P34 | A | DNA Logic Gates & Bio-computing | 25.0 | MODERATE | DNA-based carriers score high | Douglas SM et al (2012) Science 335:831 |
| P35 | A | Microgravity Formulation Engine | 100.0 | LOW | Sedimentation-Péclet proxy; smaller = better | Reichert B et al (2019) NPJ Microgravity 5:18 |
| P36 | A | Geopolitical Supply-Chain Resilience | 60.0 | MODERATE | Supplier-diversity index by carrier + ligand | FDA Drug Shortage analysis |
| P37 | A | Eco-Destructible Pharma | 60.0 | MODERATE | Biodegradability index by carrier class | Boxall ABA (2004) EMBO Rep 5:1110 |
| P38 | A | Glymphatic Clearance Trap | 100.0 | MODERATE | Stokes-Einstein: optimum 80-150 nm | Iliff JJ et al (2012) Sci Transl Med 4:147ra111 |
| P39 | A | Microglial Activation & Neuroinflammation | 100.0 | MODERATE | 100 - (cationic_charge + carrier_risk - PEG_protection) | Hickman SE et al (2018) Nat Neurosci 21:1359 |
| P40 | A | Intranasal-to-Brain Delivery | 55.0 | MODERATE | Mucoadhesion + thermo-responsive boost | Illum L (2003) J Pharm Pharmacol 56:3 |
| P41 | A | Exosome Cargo Loading Thermodynamics | 40.0 | LOW | Not an exosome carrier — N/A | Alvarez-Erviti L et al (2011) Nat Biotechnol 29:34 |
| P42 | A | Region-Specific Spatiotemporal Navigation | 75.0 | MODERATE | Ligand-region specificity table | Nutt DJ & Need AC (2014) Lancet Psychiatry 1:78 |
| P43 | A | FUS-Responsive Nanocarriers | 25.0 | MODERATE | FUS-response by carrier acoustic properties | Hynynen K & Jolesz FA (1998) Ultrasound Med Biol 2 |
| P44 | A | CNS-Specific PBPK Time-Machine | 1.0 | MODERATE | AUC over 24h therapeutic window proxy | Bies RR et al (2019) Annu Rev Pharmacol Toxicol 59 |
| P45 | C | FDA 21 CFR Part 11 Compliance | 0.0 | — | skipped_deep_validation_insufficient | |
| P46 | A | Polypharmacy & DDI Simulator | 100.0 | MODERATE | CYP-inhibition heuristic from SMILES | Jamei M et al (2009) Br J Clin Pharmacol 67:472 |
| P47 | B | Free Energy Perturbation (FEP+) | 90.0 | LOW | Vina-like ΔG proxy from MW + LogP (deep mode runs full FEP+) | Wang L et al (2015) JACS 137:2695 |
| P48 | A | Off-Target Toxicity & QSAR (50-receptor) | 100.0 | MODERATE | 50-receptor QSAR surrogate (hERG, 5HT2B, AhR risks) | Bowes J et al (2012) Nat Rev Drug Discov 11:909 |
| P49 | A | Organ-on-a-Chip Simulator | 80.0 | MODERATE | Microfluidic compatibility (size + PDI) | Bhatia SN & Ingber DE (2014) Nat Biotechnol 32:760 |
| P50 | A | Cryo-Chain Thermal Excursion Predictor | 71.5 | MODERATE | Distance from -20°C phase transition × 1.3 | Crommelin DJA et al (2021) Int J Pharm 593:120163 |
| P51 | A | Terminal Sterilization Survivability | 60.0 | MODERATE | Carrier gamma-radiation survival (25 kGy) | Reid BD (1995) J Pharm Sci Technol 49:83 |
| P52 | A | Continuous Manufacturing Digital Twin | 60.0 | MODERATE | Continuous-process readiness by carrier | Lee SL et al (2015) J Pharm Innov 10:191 |
| P53 | A | Dark Data & Negative Results Vault | 100.0 | MODERATE | Similarity-to-documented-failure | Begley CG & Ellis LM (2012) Nature 483:531 |
| P54 | A | Pharmacogenomic-Guided Targeting | 75.0 | MODERATE | Class-based pharmacogenomic applicability | Whirl-Carrillo M et al (2012) Clin Pharmacol Ther |
| P55 | C | Automated Grant & NIH Proposal Generator | 0.0 | — | skipped_deep_validation_insufficient | |
| P56 | C | Patentability Score Engine | 0.0 | — | skipped_deep_validation_insufficient | |
| P57 | A | Microfluidics & LNP Synthesis Digital Twin | 50.0 | MODERATE | Microfluidic readiness for size 50-150 nm | Belliveau NM et al (2012) Mol Ther Nucleic Acids 1 |
| P58 | A | Impurity Cascade Predictor | 80.0 | MODERATE | Carrier residual-metals impurity profile | ICH Q3D Elemental Impurities |
| P59 | A | 4D Shape-Shifting Carriers | 30.0 | MODERATE | Stimuli-responsive bonus by release kinetics | Stuart MAC et al (2010) Nat Mater 9:101 |
| P60 | A | Swarm Nanorobotics Intelligence | 15.0 | LOW | Swarm capability (most carriers: no) | Servant A et al (2015) Sci Robot 1:eaaq1155 |
| P61 | A | Synthetic Clinical Trials & Virtual Humans | 30.1 | MODERATE | Virtual-cohort responder fraction | Polasek TM & Rostami-Hodjegan A (2020) AAPS J 22:9 |
| P62 | A | Biobetter / Supergeneric Generator | 65.0 | LOW | Novelty distance from on-market CNS DDS | Ekins S et al (2019) Drug Discov Today 24:2104 |
ApoE-LNP: composite CNS-principle score = 76.3/100 (GOOD). Carrier: lnp, size 0.0 nm, ζ +0.0 mV, ligand: ApoE. Strongest group: G4 Safety (94.7/100); weakest: G8 Translational (0.0/100). Evaluated against all 57 Class A surrogate principles.
Combined score (surrogate pass-through + real physics): 11/28 principles scored PASSED (39.3%). Of these, only 7/28 principles ran independent deep computation (passed 3/7 = 42.9%); the rest re-used their Class-A surrogate score pending a future full-physics HPC run. Cite independent_pct, not pct, as evidence of physics-based validation.
| Principle | Validated | Score | Value | Confidence | Method | Narrative |
|---|---|---|---|---|---|---|
| P01 | ❌ | 53.4 | 53.38 | LOW | Full MD stress simulation — surrogate value confirmed (full-physics HPC deferred) | Full MD stress simulation: surrogate score 53.38 NEEDS REVIEW. Full deep simulation requires external HPC. |
| P02 | ✅ | 75.0 | 29.1 | MODERATE | Multi-parameter allometric scaling (Mahmood 2007): half-life ∝ BW^0.25, clearance ∝ BW^0.75, volume | Predicted human t½ = 29.1h (scaled from 4.0h mouse), clearance scales by 384.9×, volume by 2800.0×. Drug type: oligonucleotide. |
| P04 | ❌ | 27.1 | 0.1353 | LOW | Full QM tunneling (QCElemental + ASE) — surrogate value confirmed (full-physics HPC deferred) | Full QM tunneling (QCElemental + ASE): surrogate score 27.07 NEEDS REVIEW. Full deep simulation requires external HPC. |
| P08 | ❌ | 43.0 | 43.0 | LOW | Full radical-chain reaction MD — surrogate value confirmed (full-physics HPC deferred) | Full radical-chain reaction MD: surrogate score 43.0 NEEDS REVIEW. Full deep simulation requires external HPC. |
| P10 | ✅ | 60.0 | 60.0 | MODERATE | Constant-pH MD simulation — surrogate value confirmed (full-physics HPC deferred) | Constant-pH MD simulation: surrogate score 60.0 PASSED. Full deep simulation requires external HPC. |
| P11 | ✅ | 100.0 | 100 | MODERATE | DFT bond dissociation energies — surrogate value confirmed (full-physics HPC deferred) | DFT bond dissociation energies: surrogate score 100.0 PASSED. Full deep simulation requires external HPC. |
| P12 | ✅ | 83.0 | 83.0 | MODERATE | Stage-specific PBPK with full BBB physiology — surrogate value confirmed (full-physics HPC deferred) | Stage-specific PBPK with full BBB physiology: surrogate score 83.0 PASSED. Full deep simulation requires external HPC. |
| P13 | ❌ | 4.2 | 0.0021 | MODERATE | 3-compartment PBPK ODE (scipy.integrate.odeint): blood ⇌ brain ⇌ peripheral, 24h time course. k_bb_i | Brain AUC = 1.25 units·h, plasma AUC = 590.14 units·h, ratio = 0.0021. Cmax_brain = 0.06 at t = 12.8h. BELOW THRESHOLD AUC ratio. |
| P16 | ❌ | 48.0 | 48.0 | LOW | CFD of 1000L bioreactor — surrogate value confirmed (full-physics HPC deferred) | CFD of 1000L bioreactor: surrogate score 48.0 NEEDS REVIEW. Full deep simulation requires external HPC. |
| P18 | ✅ | 92.0 | -9.2 | HIGH | MM/GBSA-style ΔG estimate from validated ligand-receptor Kd database. Full atomistic docking deferre | Ligand 'apoe' → receptor 'LRP1', ΔG = -9.2 kcal/mol. STRONG BBB-targeting. |
| P23 | ✅ | 80.0 | 80.0 | MODERATE | CSP via DFT — surrogate value confirmed (full-physics HPC deferred) | CSP via DFT: surrogate score 80.0 PASSED. Full deep simulation requires external HPC. |
| P24 | ❌ | 59.6 | 59.64 | LOW | Full CFD + MD coupling — surrogate value confirmed (full-physics HPC deferred) | Full CFD + MD coupling: surrogate score 59.64 NEEDS REVIEW. Full deep simulation requires external HPC. |
| P29 | ✅ | 65.0 | 65 | MODERATE | Full membrane-fusion MD — surrogate value confirmed (full-physics HPC deferred) | Full membrane-fusion MD: surrogate score 65 PASSED. Full deep simulation requires external HPC. |
| P30 | ❌ | 45.0 | 45.0 | LOW | Full QM/MM (PySCF or ORCA) — surrogate value confirmed (full-physics HPC deferred) | Full QM/MM (PySCF or ORCA): surrogate score 45.0 NEEDS REVIEW. Full deep simulation requires external HPC. |
| P31 | ❌ | 40.0 | 0.02 | MODERATE | 7-organ whole-body distribution with size + charge + ligand-status modifiers. | Brain uptake = 0.02%, liver = 16.3%, spleen = 7.8%. INSUFFICIENT BRAIN UPTAKE. |
| P33 | ❌ | 54.6 | 54.6 | LOW | Atomistic docking + SMD pulling — surrogate value confirmed (full-physics HPC deferred) | Atomistic docking + SMD pulling: surrogate score 54.6 NEEDS REVIEW. Full deep simulation requires external HPC. |
| P38 | ✅ | 96.1 | 9.6 | HIGH | Stokes-Einstein D = k_B·T/(6πηr) at 37°C, η_CSF = 7×10⁻⁴ Pa·s. Brain residence scaled to 50-nm refer | D_CSF = 8.11 µm²/s, brain residence ≈ 9.6h. IDEAL (target 6-48h). |
| P40 | ❌ | 55.0 | 55 | LOW | Full nasal cavity CFD — surrogate value confirmed (full-physics HPC deferred) | Full nasal cavity CFD: surrogate score 55 NEEDS REVIEW. Full deep simulation requires external HPC. |
| P41 | ❌ | 40.0 | 40 | LOW | Full membrane mechanics MD — surrogate value confirmed (full-physics HPC deferred) | Full membrane mechanics MD: surrogate score 40 NEEDS REVIEW. Full deep simulation requires external HPC. |
| P43 | ❌ | 25.0 | 25 | LOW | Full acoustic radiation force MD — surrogate value confirmed (full-physics HPC deferred) | Full acoustic radiation force MD: surrogate score 25 NEEDS REVIEW. Full deep simulation requires external HPC. |
| P44 | ❌ | 0.0 | 0.0 | MODERATE | 4-compartment CNS-PBPK ODE with glymphatic clearance: Blood ⇌ Brain_ECF → CSF → Blood. Stokes-Einste | Therapeutic window = 0.0h (brain ≥ 5% dose). Brain AUC = 1.0, Cmax = 0.06. NEEDS DOSE INCREASE. |
| P47 | ❌ | 73.8 | -6.71 | LOW — LIE approximation only | LIE approximation (fallback — Vina unavailable) | Predicted ΔG_binding = -6.71 kcal/mol (LIE approximation (fallback — Vina unavailable)). MODERATE affinity. |
| P50 | ✅ | 71.5 | 71.5 | MODERATE | Full coarse-grained MD lipid phase transition — surrogate value confirmed (full-physics HPC deferred | Full coarse-grained MD lipid phase transition: surrogate score 71.5 PASSED. Full deep simulation requires external HPC. |
| P51 | ✅ | 60.0 | 60 | MODERATE | Full radical-chain damage MD — surrogate value confirmed (full-physics HPC deferred) | Full radical-chain damage MD: surrogate score 60 PASSED. Full deep simulation requires external HPC. |
| P57 | ❌ | 50.0 | 50 | LOW | Full CFD of mixer geometry — surrogate value confirmed (full-physics HPC deferred) | Full CFD of mixer geometry: surrogate score 50 NEEDS REVIEW. Full deep simulation requires external HPC. |
| P58 | ✅ | 80.0 | 80 | MODERATE | Full QM/MM cascade simulation — surrogate value confirmed (full-physics HPC deferred) | Full QM/MM cascade simulation: surrogate score 80 PASSED. Full deep simulation requires external HPC. |
| P59 | ❌ | 30.0 | 30 | LOW | Full coarse-grained MD morphological transition — surrogate value confirmed (full-physics HPC deferr | Full coarse-grained MD morphological transition: surrogate score 30 NEEDS REVIEW. Full deep simulation requires external HPC. |
| P61 | ❌ | 30.1 | 30.0 | LOW | Full Monte-Carlo population PBPK — surrogate value confirmed (full-physics HPC deferred) | Full Monte-Carlo population PBPK: surrogate score 30.12 NEEDS REVIEW. Full deep simulation requires external HPC. |
Translational outputs for Nusinersen's validated Top-1 DDS. These are NOT used for ranking — they are administrative deliverables triggered only AFTER deep physics validation passes.
Deep validation passed only 11/28 principles. Translational deliverables withheld until a higher-ranked DDS passes deep validation.
Deep validation passed only 11/28 principles. Translational deliverables withheld until a higher-ranked DDS passes deep validation.
Deep validation passed only 11/28 principles. Translational deliverables withheld until a higher-ranked DDS passes deep validation.
Deep validation passed only 11/28 principles. Translational deliverables withheld until a higher-ranked DDS passes deep validation.
Deep validation passed only 11/28 principles. Translational deliverables withheld until a higher-ranked DDS passes deep validation.
For Nusinersen: each candidate DDS that was tried in the Class B deep validation phase. If the Top-1 fails the 70% threshold, we fall back to Top-2, then Top-3 — with explicit reasons recorded.
| Rank | DDS | Surrogate | Verdict | Promoted? | Failure Reason | Transition Reason |
|---|---|---|---|---|---|---|
| #1 | ApoE-LNP | 76.28 | FAILED 39.3% (11/28) |
— | Deep validation FAILED: only 11/28 principles validated (39.3%, threshold 70%). Critical failures: P01, P04, P08, P13, P16. | Falling back to rank #2 because deep physics showed insufficient evidence for this DDS. |
| #2 | AAV9-vector | 64.16 | FAILED 32.1% (9/28) |
— | Deep validation FAILED: only 9/28 principles validated (32.1%, threshold 70%). Critical failures: P01, P04, P08, P13, P16. | Falling back to rank #3 because deep physics showed insufficient evidence for this DDS. |
| #3 | RVG29-Liposome-pH | 54.09 | FAILED 39.3% (11/28) |
— | Deep validation FAILED: only 11/28 principles validated (39.3%, threshold 70%). Critical failures: P01, P04, P08, P13, P16. | No more candidates in Top-3 — reverting to rank #1 and reporting with FAILED verdict. Researcher should reformulate. |